Liquidia Technologies

Company Summary: Transaction(s) Overview:  2013 – 2018
  • The Bill & Melinda Gates Foundation  makes its first-ever equity investment
  • GSK completes a $10 million investment, along with a co-development partnership valued at $375 million
  • Envisia Therapeutics is created though the “spin-off” of ophthalmology assets, in conjunction with a $25 million investment by Canaan Partners, NEA, Morningside and Pappas
  • Company completes a $22.5 million pre-IPO transaction, led by Xeraya
  • Company completes a $9.5 million IPO cornerstone and staple investment, led by OCBC Bank (Singapore), CrossInvest (Asia) and a syndicate of global growth investors
  • Company receives pre-clearance from the Singapore Exchange (“SGX”) associated with an Initial Public Offering (“IPO”) of Common Stock
  • Company completes a Series D offering in the amount of $30 million, led by Amereus, Ltd.
  • Company files S-1 Registration Statement with the SEC relating to an IPO on NASDAQ
Significance of the Transaction: Healthios Role:
  • Healthios served as strategic and financial advisor to Liquidia
  • This transaction underscores Healthios’ commitment to capital formation, to Pre-IPO & IPO’s for emerging growth companies, to our global reach, and
  • To serving the financing, strategic AND liquidity objectives of the most promising companies at the peak of their potential